Loading...
•
Sep 30, 2022
Veru Q4 2022 Earnings Report
Veru reported financial results for Q4 2022 and provided a business update.
Key Takeaways
Veru Inc. reported its fiscal 2022 fourth quarter and full year financial results. The company is preparing for commercialization of sabizabulin, while also working to regenerate FC2 product sales.
U.S. FDA reviewing EUA application for sabizabulin to treat hospitalized COVID-19 patients at high risk for ARDS
European Medicines Agency’s (EMA) Emergency Task Force reviewing sabizabulin for emergency use in EU member states
Sabizabulin also under review for potential emergency authorization by MHRA (UK), TGA (Australia), and Health Canada
Veru preparing for U.S. and international commercialization and distribution of sabizabulin, and manufacturing capacity for drug supply in place
Forward Guidance
The statements in the release that are not historical facts are forward-looking statements which are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...